Cargando…

Bioinformatics analysis based on DNA methylation data identified in lung adenocarcinoma subgroups with different immune characteristics and clinical outcomes

BACKGROUND: DNA methylation can be used to predict clinical outcomes and improve the classification of tumors. The present study aimed to develop a new lung adenocarcinoma (LUAD) classification system according to the immune cell gene-related methylation sites and to reveal the survival outcomes, cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Ruilin, Huang, Xiaoming, Lin, Junqi, Lin, Shaoming, Shen, Guanle, Chen, Wenbiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183559/
https://www.ncbi.nlm.nih.gov/pubmed/37197548
http://dx.doi.org/10.21037/jtd-23-494
_version_ 1785041977989922816
author Yu, Ruilin
Huang, Xiaoming
Lin, Junqi
Lin, Shaoming
Shen, Guanle
Chen, Wenbiao
author_facet Yu, Ruilin
Huang, Xiaoming
Lin, Junqi
Lin, Shaoming
Shen, Guanle
Chen, Wenbiao
author_sort Yu, Ruilin
collection PubMed
description BACKGROUND: DNA methylation can be used to predict clinical outcomes and improve the classification of tumors. The present study aimed to develop a new lung adenocarcinoma (LUAD) classification system according to the immune cell gene-related methylation sites and to reveal the survival outcomes, clinical characteristics, immune cell infiltration, stem cell characteristics, and genomic variations of each molecular subgroup. METHODS: The DNA methylation sites of LUAD samples collected from The Cancer Genome Atlas (TCGA) database were analyzed, and the prognosis-related differential methylation sites (DMS) were screened. Consistent clustering of the samples was conducted using ConsensusClusterPlus, and the classification results were verified by principal component analysis (PCA). The survival and clinical results, immune cell infiltration, stemness, DNA mutation, and copy number variation (CNV) of each molecular subgroup were analyzed. RESULTS: A total of 40 DMS were obtained by difference and univariate COX analyses, and the TCGA LUAD samples were divided into three subgroups: cluster 1 (C1), cluster 2 (C2), and cluster 3 (C3). Among these subgroups, the overall survival (OS) of C3 was significantly higher than that of C1 and C2. Compared with C1 and C3, C2 had the lowest innate immune cell and adaptive immune cell infiltration scores; the lowest stromal score, immune score, and iconic immune checkpoint expression; and the highest expression of messenger RNA (mRNA) expression-based stemness indices (mRNAsi), DNA methylation-based stemness index (mDNAsi), and tumor mutational burden (TMB). CONCLUSIONS: In this study, we proposed a LUAD typing system based on DMS, which was closely related to the survival, clinical features, immune characteristics, and genomic variations of LUAD, and may contribute to the development of personalized therapy for new specific subtypes.
format Online
Article
Text
id pubmed-10183559
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-101835592023-05-16 Bioinformatics analysis based on DNA methylation data identified in lung adenocarcinoma subgroups with different immune characteristics and clinical outcomes Yu, Ruilin Huang, Xiaoming Lin, Junqi Lin, Shaoming Shen, Guanle Chen, Wenbiao J Thorac Dis Original Article BACKGROUND: DNA methylation can be used to predict clinical outcomes and improve the classification of tumors. The present study aimed to develop a new lung adenocarcinoma (LUAD) classification system according to the immune cell gene-related methylation sites and to reveal the survival outcomes, clinical characteristics, immune cell infiltration, stem cell characteristics, and genomic variations of each molecular subgroup. METHODS: The DNA methylation sites of LUAD samples collected from The Cancer Genome Atlas (TCGA) database were analyzed, and the prognosis-related differential methylation sites (DMS) were screened. Consistent clustering of the samples was conducted using ConsensusClusterPlus, and the classification results were verified by principal component analysis (PCA). The survival and clinical results, immune cell infiltration, stemness, DNA mutation, and copy number variation (CNV) of each molecular subgroup were analyzed. RESULTS: A total of 40 DMS were obtained by difference and univariate COX analyses, and the TCGA LUAD samples were divided into three subgroups: cluster 1 (C1), cluster 2 (C2), and cluster 3 (C3). Among these subgroups, the overall survival (OS) of C3 was significantly higher than that of C1 and C2. Compared with C1 and C3, C2 had the lowest innate immune cell and adaptive immune cell infiltration scores; the lowest stromal score, immune score, and iconic immune checkpoint expression; and the highest expression of messenger RNA (mRNA) expression-based stemness indices (mRNAsi), DNA methylation-based stemness index (mDNAsi), and tumor mutational burden (TMB). CONCLUSIONS: In this study, we proposed a LUAD typing system based on DMS, which was closely related to the survival, clinical features, immune characteristics, and genomic variations of LUAD, and may contribute to the development of personalized therapy for new specific subtypes. AME Publishing Company 2023-04-27 2023-04-28 /pmc/articles/PMC10183559/ /pubmed/37197548 http://dx.doi.org/10.21037/jtd-23-494 Text en 2023 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Yu, Ruilin
Huang, Xiaoming
Lin, Junqi
Lin, Shaoming
Shen, Guanle
Chen, Wenbiao
Bioinformatics analysis based on DNA methylation data identified in lung adenocarcinoma subgroups with different immune characteristics and clinical outcomes
title Bioinformatics analysis based on DNA methylation data identified in lung adenocarcinoma subgroups with different immune characteristics and clinical outcomes
title_full Bioinformatics analysis based on DNA methylation data identified in lung adenocarcinoma subgroups with different immune characteristics and clinical outcomes
title_fullStr Bioinformatics analysis based on DNA methylation data identified in lung adenocarcinoma subgroups with different immune characteristics and clinical outcomes
title_full_unstemmed Bioinformatics analysis based on DNA methylation data identified in lung adenocarcinoma subgroups with different immune characteristics and clinical outcomes
title_short Bioinformatics analysis based on DNA methylation data identified in lung adenocarcinoma subgroups with different immune characteristics and clinical outcomes
title_sort bioinformatics analysis based on dna methylation data identified in lung adenocarcinoma subgroups with different immune characteristics and clinical outcomes
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183559/
https://www.ncbi.nlm.nih.gov/pubmed/37197548
http://dx.doi.org/10.21037/jtd-23-494
work_keys_str_mv AT yuruilin bioinformaticsanalysisbasedondnamethylationdataidentifiedinlungadenocarcinomasubgroupswithdifferentimmunecharacteristicsandclinicaloutcomes
AT huangxiaoming bioinformaticsanalysisbasedondnamethylationdataidentifiedinlungadenocarcinomasubgroupswithdifferentimmunecharacteristicsandclinicaloutcomes
AT linjunqi bioinformaticsanalysisbasedondnamethylationdataidentifiedinlungadenocarcinomasubgroupswithdifferentimmunecharacteristicsandclinicaloutcomes
AT linshaoming bioinformaticsanalysisbasedondnamethylationdataidentifiedinlungadenocarcinomasubgroupswithdifferentimmunecharacteristicsandclinicaloutcomes
AT shenguanle bioinformaticsanalysisbasedondnamethylationdataidentifiedinlungadenocarcinomasubgroupswithdifferentimmunecharacteristicsandclinicaloutcomes
AT chenwenbiao bioinformaticsanalysisbasedondnamethylationdataidentifiedinlungadenocarcinomasubgroupswithdifferentimmunecharacteristicsandclinicaloutcomes